Oxford BioMedica
Discover Realise

Platform technologies

Lentivector platform delivery technologies

A unique integrated platform

Underpinned by a unique integrated platform, which combines our intellectual property (IP), know-how and facilities, we are recognised as a world leader in the development of Advanced Therapy Medicinal Products (ATMPs), particularly gene and cell therapy products.

Our technology is protected by a more extensive patent portfolio covering lentiviral technology than any other commercial organisation or academic institution.

Taken together, our patents, know-how and in-house capabilities give us an industry-leading platform on which we can develop gene and cell therapy products.

Our pioneering therapies

Our gene therapy product candidates that use our LentiVector® technology to treat eye disorders, central nervous system (CNS) candidates in Parkinson’s disease (PD), and oncology. At Oxford BioMedica we are using our LentiVector® technology combined with the 5T4 antigen for example CART-5T4  and this has high potential in target solid tumours. In addition, we are exploring other research concepts with a view to identifying further candidates to bring into pre-clinical development over the next two to three years.

Our exclusive technology

Although the primary purpose of our in-house resources is to support the development of our own product pipeline, we are regularly approached by third parties who want to access our skill sets, know-how and capacity. We have started to earn significant revenues from bioprocessing lentiviral vectors for third parties.

Related products:
Priority programmes
•    OXB-102
•    OXB-202
•    OXB-302
Other candidates
•    OXB-201 (RetinoStat®)
•    OXB-301 (Trovax®)

Partnered / IP enabled royalty bearing products
•    SAR 422459 (Sanofi)
•    SAR 421869 (Sanofi)
•    CTL-019 (Novartis)
•    Undisclosed CAR-T (Novartis)
•    LV305 (Immune Design)
•    Undisclosed (GSK)
•    Undisclosed (GSK)


Priority programmes (to be spun out or out-licensed)

Read in full

Related products:

Click on a product to read in full

Other candidates (to be spun out or out-licensed)

Read in full

Related products:

Click on a product to read in full

Oxford BioMedica partnered products (development milestones and royalties)

Read in full

Related products:

Click on a product to read in full

IP enabled and royalty bearing products (process development and bioprocessing revenues, and royalties)

Read in full

Related products:

Click on a product to read in full

LentiVector® platform

Our LentiVector® delivery platform is an advanced lentiviral vector based gene delivery system designed to overcome the safety & delivery problems associated with earlier generations of vector systems. It can stably deliver genes into cells with up to 100% efficiency & can integrate genes into non-dividing cells including neurons in the brain & retinal cells in the eye. In such cell types, studies suggest that gene expression could be maintained indefinitely, & the Company presented data in May 2016 indicating ground-breaking long-term four-year sustained &, in one of the studies, dose-dependent gene expression. The LentiVector® delivery platform technology also has a larger capacity than most other vector systems & can accommodate multiple therapeutic genes.

Read in full

Related products:

Click on a product to read in full

5T4 Tumour Antigen

The 5T4 tumour antigen is a unique protein found on most common types of solid cancer. It is potentially a valuable target for novel anti-cancer interventions given its restricted expression in normal tissues and its high prevalence on the surface of both primary and metastatic cancerous cells. The 5T4 tumour antigen was identified through research into the similarities between the development of the placenta during pregnancy and the progression of cancer. 5T4 is produced by both cancerous cells and also by placental and foetal cells, suggesting that the process of immunological escape in pregnancy and cancer is based on similar mechanisms. We are now combining 5T4 with CAR-T to create our own OXB-302 and this has shown great potential in treating solid tumours

Read in full

Related products:

Click on a product to read in full

OXB-302 (CAR-T 5T4®)

The Group is developing a product which combines the LentiVector® technology platform with 5T4. The product is based on a gene modified autologous T-cell which is engineered using a lentiviral vector to express an antibody against 5T4. The T-cell is then infused into the patient where it recognises the 5T4 tumour antigen and triggers the “normal” T-cell killing mechanisms which kills the cancer cell. This innovative approach directly primes the immune system against the 5T4 antigen, by presenting the antigen on T-cells which are responsible for detecting foreign antigens. This new product is currently in pre-clinical stage development.

Read in full

Related products:

Click on a product to read in full